Table 3 Immunoreactivity of KGHR1-scFv antibody in human tumour tissues and cell lines
Immunoreactivity (HSCOREsa) | Immunocytochemistry | ||||
|---|---|---|---|---|---|
Tumour tissues | Cases | Primary tumour tissues | Normal tissues | Tumour cell lines | Results |
Colorectal cancer | 30 | 180.54 ± 79.21 | 7.31 ± 2.13 | BGC853 | + |
Gastric cancer | 25 | 150.17 ± 64.31 | 7.13 ± 1.99 | MKN28 | + |
Oesophageal cancer | 25 | 151.42 ± 59.13 | 8.21 ± 2.38 | HCT116 | + |
Bladder cancer | 25 | 149.37 ± 79.27 | 7.23 ± 2.15 | QGY7703 | + |
Lung adenocarcinoma | 20 | 199.45 ± 69.11 | 8.13 ± 2.17 | SMMC-7721 | + |
Lung squamous cell carcinoma | 20 | 185.37 ± 71.64 | 7.53 ± 2.23 | HepG2 | + |
Lung small cell carcinoma | 19 | 146.25 ± 83.00 | 7.78 ± 2.17 | MDA-MB-231 | + |
Papillary thyroid carcinoma | 20 | 191.67 ± 82.71 | 7.93 ± 2.76 | MDA-MB-435 | + |
Hepatocarcinoma | 22 | 168.25 ± 79.33 | 8.47 ± 3.18 | MCF7 | + |
Prostate carcinoma | 25 | 145.37 ± 75.35 | 8.52 ± 3.43 | HeLa | + |
Breast cancer | 24 | 165.73 ± 63.28 | 7.93 ± 2.56 | SKOV3 | + |
Endometrial cancer | 30 | 153.32 ± 57.00 | 8.73 ± 3.63 | Hep2 | + |
Glioma | 20 | 131.50 ± 42.59 | 10.28 ± 5.00 | T24 | + |
Renal cell carcinoma | 24 | 89.61 ± 53.73 | 11.27 ± 4.91 |  |  |